Recombinant activated factor VII to control life-threatening haemorrhagic radiation cystitis.
BACKGROUND
The use of recombinant activated factor VII has been described for many clinical scenarios, but the value of this therapeutic agent for life-threatening haemorrhagic cystitis remains novel.


METHODS
We describe a case of persistent life-threatening haemorrhagic radiation cystitis, and discuss current knowledge of this therapy including potential complications.


RESULTS
Control of haemorrhage was successfully achieved only after use of this agent.


CONCLUSIONS
This therapy deserves mention in any future management algorithm devised for this condition.
Connolly
S S
SS
Department of Urology, University College Hospital Galway, Galway, Ireland. steconnolly@rcsi.ie
D'Arcy
F T
FT
Corcoran
M O
MO
D000230:Adenocarcinoma / Q000532:radiotherapy; D003556:Cystitis / Q000188:drug therapy* / Q000209:etiology; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use*; D017809:Fatal Outcome; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011832:Radiation Injuries / Q000150:complications*; D011879:Radiotherapy Dosage; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000532:radiotherapy; D012811:Sigmoid Neoplasms / Q000532:radiotherapy
D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa